Ipca Laboratories Limited (BSE: IPCALAB.BO) Stock Competitors & Peer Comparison
See IPCALAB.BO's competitors and their performance on the BSE and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for IPCALAB.BO and its BSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| IPCALAB.BO | ₹1,939.15 | -0.63% | 497.4B | 36.76 | ₹52.94 | +0.31% |
| SUNPHARMA.NS | ₹1,781.00 | +0.07% | 4.3T | 35.04 | ₹51.48 | +0.89% |
| SUNPHARMA.BO | ₹1,783.25 | +0.07% | 4.3T | 35.31 | ₹51.00 | +0.89% |
| DIVISLAB.BO | ₹9,580.00 | +3.99% | 2.5T | 86.62 | ₹110.19 | +0.31% |
| DIVISLAB.NS | ₹9,588.00 | +4.26% | 2.5T | 86.70 | ₹110.15 | +0.31% |
| TORNTPHARM.BO | ₹4,710.00 | -0.95% | 1.8T | 72.50 | ₹65.90 | +0.80% |
| TORNTPHARM.NS | ₹4,716.20 | -1.17% | 1.8T | 71.50 | ₹66.74 | +0.80% |
| ZYDUSLIFE.BO | ₹1,154.00 | +1.36% | 1.2T | 27.32 | ₹42.46 | +0.09% |
| ZYDUSLIFE.NS | ₹1,153.00 | +1.23% | 1.2T | 27.15 | ₹42.71 | +0.09% |
| LAURUSLABS.BO | ₹2,055.00 | +4.63% | 1.1T | 101.13 | ₹20.31 | +0.10% |
Stock Comparison
Sun Pharmaceutical Industries Limited (NSE: SUNPHARMA.NS)
IPCALAB.BO vs SUNPHARMA.NS Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, SUNPHARMA.NS has a market cap of 4.3T. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while SUNPHARMA.NS trades at ₹1,781.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas SUNPHARMA.NS's P/E ratio is 35.04. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to SUNPHARMA.NS's ROE of +0.15%. Regarding short-term risk, IPCALAB.BO is less volatile compared to SUNPHARMA.NS. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check SUNPHARMA.NS's competition here
Sun Pharmaceutical Industries Limited (BSE: SUNPHARMA.BO)
IPCALAB.BO vs SUNPHARMA.BO Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, SUNPHARMA.BO has a market cap of 4.3T. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while SUNPHARMA.BO trades at ₹1,783.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas SUNPHARMA.BO's P/E ratio is 35.31. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to SUNPHARMA.BO's ROE of +0.15%. Regarding short-term risk, IPCALAB.BO is less volatile compared to SUNPHARMA.BO. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check SUNPHARMA.BO's competition here
Divi's Laboratories Limited (BSE: DIVISLAB.BO)
IPCALAB.BO vs DIVISLAB.BO Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, DIVISLAB.BO has a market cap of 2.5T. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while DIVISLAB.BO trades at ₹9,580.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas DIVISLAB.BO's P/E ratio is 86.62. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to DIVISLAB.BO's ROE of +0.18%. Regarding short-term risk, IPCALAB.BO is less volatile compared to DIVISLAB.BO. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check DIVISLAB.BO's competition here
Divi's Laboratories Limited (NSE: DIVISLAB.NS)
IPCALAB.BO vs DIVISLAB.NS Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, DIVISLAB.NS has a market cap of 2.5T. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while DIVISLAB.NS trades at ₹9,588.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas DIVISLAB.NS's P/E ratio is 86.70. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to DIVISLAB.NS's ROE of +0.18%. Regarding short-term risk, IPCALAB.BO is less volatile compared to DIVISLAB.NS. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check DIVISLAB.NS's competition here
Torrent Pharmaceuticals Limited (BSE: TORNTPHARM.BO)
IPCALAB.BO vs TORNTPHARM.BO Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, TORNTPHARM.BO has a market cap of 1.8T. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while TORNTPHARM.BO trades at ₹4,710.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas TORNTPHARM.BO's P/E ratio is 72.50. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to TORNTPHARM.BO's ROE of +0.20%. Regarding short-term risk, IPCALAB.BO is less volatile compared to TORNTPHARM.BO. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check TORNTPHARM.BO's competition here
Torrent Pharmaceuticals Limited (NSE: TORNTPHARM.NS)
IPCALAB.BO vs TORNTPHARM.NS Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, TORNTPHARM.NS has a market cap of 1.8T. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while TORNTPHARM.NS trades at ₹4,716.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas TORNTPHARM.NS's P/E ratio is 71.50. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to TORNTPHARM.NS's ROE of +0.20%. Regarding short-term risk, IPCALAB.BO is less volatile compared to TORNTPHARM.NS. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check TORNTPHARM.NS's competition here
Zydus Lifesciences Limited (BSE: ZYDUSLIFE.BO)
IPCALAB.BO vs ZYDUSLIFE.BO Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, ZYDUSLIFE.BO has a market cap of 1.2T. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while ZYDUSLIFE.BO trades at ₹1,154.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas ZYDUSLIFE.BO's P/E ratio is 27.32. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to ZYDUSLIFE.BO's ROE of +0.16%. Regarding short-term risk, IPCALAB.BO is less volatile compared to ZYDUSLIFE.BO. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check ZYDUSLIFE.BO's competition here
Zydus Lifesciences Limited (NSE: ZYDUSLIFE.NS)
IPCALAB.BO vs ZYDUSLIFE.NS Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, ZYDUSLIFE.NS has a market cap of 1.2T. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while ZYDUSLIFE.NS trades at ₹1,153.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas ZYDUSLIFE.NS's P/E ratio is 27.15. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to ZYDUSLIFE.NS's ROE of +0.16%. Regarding short-term risk, IPCALAB.BO is less volatile compared to ZYDUSLIFE.NS. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check ZYDUSLIFE.NS's competition here
Laurus Labs Limited (BSE: LAURUSLABS.BO)
IPCALAB.BO vs LAURUSLABS.BO Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, LAURUSLABS.BO has a market cap of 1.1T. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while LAURUSLABS.BO trades at ₹2,055.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas LAURUSLABS.BO's P/E ratio is 101.13. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to LAURUSLABS.BO's ROE of +0.21%. Regarding short-term risk, IPCALAB.BO is more volatile compared to LAURUSLABS.BO. This indicates higher risk in terms of short-term price fluctuations for IPCALAB.BO.Check LAURUSLABS.BO's competition here
Laurus Labs Limited (NSE: LAURUSLABS.NS)
IPCALAB.BO vs LAURUSLABS.NS Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, LAURUSLABS.NS has a market cap of 1.1T. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while LAURUSLABS.NS trades at ₹2,052.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas LAURUSLABS.NS's P/E ratio is 101.18. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to LAURUSLABS.NS's ROE of +0.21%. Regarding short-term risk, IPCALAB.BO is similarly volatile compared to LAURUSLABS.NS. This indicates similar risk in terms of short-term price fluctuations for IPCALAB.BO.Check LAURUSLABS.NS's competition here
Cipla Limited (BSE: CIPLA.BO)
IPCALAB.BO vs CIPLA.BO Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, CIPLA.BO has a market cap of 1.1T. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while CIPLA.BO trades at ₹1,329.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas CIPLA.BO's P/E ratio is 32.21. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to CIPLA.BO's ROE of +0.10%. Regarding short-term risk, IPCALAB.BO is less volatile compared to CIPLA.BO. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check CIPLA.BO's competition here
Cipla Limited (NSE: CIPLA.NS)
IPCALAB.BO vs CIPLA.NS Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, CIPLA.NS has a market cap of 1.1T. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while CIPLA.NS trades at ₹1,327.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas CIPLA.NS's P/E ratio is 32.15. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to CIPLA.NS's ROE of +0.10%. Regarding short-term risk, IPCALAB.BO is less volatile compared to CIPLA.NS. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check CIPLA.NS's competition here
Mankind Pharma Limited (NSE: MANKIND.NS)
IPCALAB.BO vs MANKIND.NS Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, MANKIND.NS has a market cap of 1T. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while MANKIND.NS trades at ₹2,500.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas MANKIND.NS's P/E ratio is 47.83. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to MANKIND.NS's ROE of +0.13%. Regarding short-term risk, IPCALAB.BO is less volatile compared to MANKIND.NS. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check MANKIND.NS's competition here
Mankind Pharma Limited (BSE: MANKIND.BO)
IPCALAB.BO vs MANKIND.BO Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, MANKIND.BO has a market cap of 1T. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while MANKIND.BO trades at ₹2,494.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas MANKIND.BO's P/E ratio is 47.54. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to MANKIND.BO's ROE of +0.13%. Regarding short-term risk, IPCALAB.BO is less volatile compared to MANKIND.BO. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check MANKIND.BO's competition here
Dr. Reddy's Laboratories Limited (BSE: DRREDDY.BO)
IPCALAB.BO vs DRREDDY.BO Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, DRREDDY.BO has a market cap of 1T. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while DRREDDY.BO trades at ₹1,202.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas DRREDDY.BO's P/E ratio is 30.43. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to DRREDDY.BO's ROE of +0.09%. Regarding short-term risk, IPCALAB.BO is less volatile compared to DRREDDY.BO. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check DRREDDY.BO's competition here
Dr. Reddy's Laboratories Limited (NSE: DRREDDY.NS)
IPCALAB.BO vs DRREDDY.NS Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, DRREDDY.NS has a market cap of 1T. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while DRREDDY.NS trades at ₹1,203.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas DRREDDY.NS's P/E ratio is 30.42. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to DRREDDY.NS's ROE of +0.09%. Regarding short-term risk, IPCALAB.BO is less volatile compared to DRREDDY.NS. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check DRREDDY.NS's competition here
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS)
IPCALAB.BO vs AUROPHARMA.NS Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, AUROPHARMA.NS has a market cap of 974B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while AUROPHARMA.NS trades at ₹1,682.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas AUROPHARMA.NS's P/E ratio is 26.45. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to AUROPHARMA.NS's ROE of +0.10%. Regarding short-term risk, IPCALAB.BO is less volatile compared to AUROPHARMA.NS. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check AUROPHARMA.NS's competition here
Aurobindo Pharma Limited (BSE: AUROPHARMA.BO)
IPCALAB.BO vs AUROPHARMA.BO Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, AUROPHARMA.BO has a market cap of 972B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while AUROPHARMA.BO trades at ₹1,685.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas AUROPHARMA.BO's P/E ratio is 26.41. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to AUROPHARMA.BO's ROE of +0.10%. Regarding short-term risk, IPCALAB.BO is less volatile compared to AUROPHARMA.BO. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check AUROPHARMA.BO's competition here
Lupin Limited (BSE: LUPIN.BO)
IPCALAB.BO vs LUPIN.BO Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, LUPIN.BO has a market cap of 927.9B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while LUPIN.BO trades at ₹2,007.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas LUPIN.BO's P/E ratio is 15.97. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to LUPIN.BO's ROE of +0.26%. Regarding short-term risk, IPCALAB.BO is more volatile compared to LUPIN.BO. This indicates higher risk in terms of short-term price fluctuations for IPCALAB.BO.Check LUPIN.BO's competition here
Lupin Limited (NSE: LUPIN.NS)
IPCALAB.BO vs LUPIN.NS Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, LUPIN.NS has a market cap of 927.9B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while LUPIN.NS trades at ₹2,012.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas LUPIN.NS's P/E ratio is 15.93. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to LUPIN.NS's ROE of +0.26%. Regarding short-term risk, IPCALAB.BO is less volatile compared to LUPIN.NS. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check LUPIN.NS's competition here
Glenmark Pharmaceuticals Limited (BSE: GLENMARK.BO)
IPCALAB.BO vs GLENMARK.BO Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, GLENMARK.BO has a market cap of 661.2B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while GLENMARK.BO trades at ₹2,286.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas GLENMARK.BO's P/E ratio is 35.94. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to GLENMARK.BO's ROE of +0.19%. Regarding short-term risk, IPCALAB.BO is less volatile compared to GLENMARK.BO. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check GLENMARK.BO's competition here
Glenmark Pharmaceuticals Limited (NSE: GLENMARK.NS)
IPCALAB.BO vs GLENMARK.NS Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, GLENMARK.NS has a market cap of 652.2B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while GLENMARK.NS trades at ₹2,282.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas GLENMARK.NS's P/E ratio is 37.88. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to GLENMARK.NS's ROE of +0.19%. Regarding short-term risk, IPCALAB.BO is less volatile compared to GLENMARK.NS. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check GLENMARK.NS's competition here
Alkem Laboratories Limited (NSE: ALKEM.NS)
IPCALAB.BO vs ALKEM.NS Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, ALKEM.NS has a market cap of 632.7B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while ALKEM.NS trades at ₹5,350.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas ALKEM.NS's P/E ratio is 29.29. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to ALKEM.NS's ROE of +0.16%. Regarding short-term risk, IPCALAB.BO is less volatile compared to ALKEM.NS. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check ALKEM.NS's competition here
Alkem Laboratories Limited (BSE: ALKEM.BO)
IPCALAB.BO vs ALKEM.BO Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, ALKEM.BO has a market cap of 629.1B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while ALKEM.BO trades at ₹5,360.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas ALKEM.BO's P/E ratio is 29.20. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to ALKEM.BO's ROE of +0.16%. Regarding short-term risk, IPCALAB.BO is less volatile compared to ALKEM.BO. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check ALKEM.BO's competition here
Gland Pharma Limited (NSE: GLAND.NS)
IPCALAB.BO vs GLAND.NS Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, GLAND.NS has a market cap of 495.9B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while GLAND.NS trades at ₹3,150.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas GLAND.NS's P/E ratio is 43.84. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to GLAND.NS's ROE of +0.11%. Regarding short-term risk, IPCALAB.BO is less volatile compared to GLAND.NS. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check GLAND.NS's competition here
Gland Pharma Limited (BSE: GLAND.BO)
IPCALAB.BO vs GLAND.BO Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, GLAND.BO has a market cap of 495.7B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while GLAND.BO trades at ₹3,151.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas GLAND.BO's P/E ratio is 43.87. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to GLAND.BO's ROE of +0.11%. Regarding short-term risk, IPCALAB.BO is less volatile compared to GLAND.BO. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check GLAND.BO's competition here
Ipca Laboratories Limited (NSE: IPCALAB.NS)
IPCALAB.BO vs IPCALAB.NS Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, IPCALAB.NS has a market cap of 493.6B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while IPCALAB.NS trades at ₹1,938.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas IPCALAB.NS's P/E ratio is 36.54. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to IPCALAB.NS's ROE of +0.16%. Regarding short-term risk, IPCALAB.BO is less volatile compared to IPCALAB.NS. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check IPCALAB.NS's competition here
Ajanta Pharma Limited (NSE: AJANTPHARM.NS)
IPCALAB.BO vs AJANTPHARM.NS Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, AJANTPHARM.NS has a market cap of 446.4B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while AJANTPHARM.NS trades at ₹3,569.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas AJANTPHARM.NS's P/E ratio is 39.38. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to AJANTPHARM.NS's ROE of +0.26%. Regarding short-term risk, IPCALAB.BO is less volatile compared to AJANTPHARM.NS. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check AJANTPHARM.NS's competition here
Ajanta Pharma Limited (BSE: AJANTPHARM.BO)
IPCALAB.BO vs AJANTPHARM.BO Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, AJANTPHARM.BO has a market cap of 446.2B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while AJANTPHARM.BO trades at ₹3,569.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas AJANTPHARM.BO's P/E ratio is 39.42. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to AJANTPHARM.BO's ROE of +0.26%. Regarding short-term risk, IPCALAB.BO is less volatile compared to AJANTPHARM.BO. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check AJANTPHARM.BO's competition here
Suven Pharmaceuticals Limited (NSE: SUVENPHAR.NS)
IPCALAB.BO vs SUVENPHAR.NS Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, SUVENPHAR.NS has a market cap of 412.4B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while SUVENPHAR.NS trades at ₹1,078.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas SUVENPHAR.NS's P/E ratio is 98.90. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to SUVENPHAR.NS's ROE of +0.03%. Regarding short-term risk, IPCALAB.BO is less volatile compared to SUVENPHAR.NS. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check SUVENPHAR.NS's competition here
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO)
IPCALAB.BO vs SUVENPHAR.BO Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, SUVENPHAR.BO has a market cap of 411.4B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while SUVENPHAR.BO trades at ₹1,075.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas SUVENPHAR.BO's P/E ratio is 98.29. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to SUVENPHAR.BO's ROE of +0.16%. Regarding short-term risk, IPCALAB.BO is less volatile compared to SUVENPHAR.BO. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check SUVENPHAR.BO's competition here
Emcure Pharmaceuticals Ltd. (NSE: EMCURE.NS)
IPCALAB.BO vs EMCURE.NS Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, EMCURE.NS has a market cap of 364.6B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while EMCURE.NS trades at ₹1,918.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas EMCURE.NS's P/E ratio is 35.14. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to EMCURE.NS's ROE of +0.21%. Regarding short-term risk, IPCALAB.BO is less volatile compared to EMCURE.NS. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check EMCURE.NS's competition here
Neuland Laboratories Limited (NSE: NEULANDLAB.NS)
IPCALAB.BO vs NEULANDLAB.NS Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, NEULANDLAB.NS has a market cap of 281.9B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while NEULANDLAB.NS trades at ₹21,655.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas NEULANDLAB.NS's P/E ratio is 55.71. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to NEULANDLAB.NS's ROE of +0.28%. Regarding short-term risk, IPCALAB.BO is less volatile compared to NEULANDLAB.NS. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check NEULANDLAB.NS's competition here
Neuland Laboratories Limited (BSE: NEULANDLAB.BO)
IPCALAB.BO vs NEULANDLAB.BO Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, NEULANDLAB.BO has a market cap of 281.4B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while NEULANDLAB.BO trades at ₹21,665.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas NEULANDLAB.BO's P/E ratio is 55.65. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to NEULANDLAB.BO's ROE of +0.28%. Regarding short-term risk, IPCALAB.BO is less volatile compared to NEULANDLAB.BO. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check NEULANDLAB.BO's competition here
Piramal Pharma Limited (NSE: PPLPHARMA.NS)
IPCALAB.BO vs PPLPHARMA.NS Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, PPLPHARMA.NS has a market cap of 265.7B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while PPLPHARMA.NS trades at ₹203.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas PPLPHARMA.NS's P/E ratio is -171.22. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to PPLPHARMA.NS's ROE of -0.04%. Regarding short-term risk, IPCALAB.BO is less volatile compared to PPLPHARMA.NS. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check PPLPHARMA.NS's competition here
Piramal Pharma Limited (BSE: PPLPHARMA.BO)
IPCALAB.BO vs PPLPHARMA.BO Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, PPLPHARMA.BO has a market cap of 264.5B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while PPLPHARMA.BO trades at ₹202.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas PPLPHARMA.BO's P/E ratio is -170.82. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to PPLPHARMA.BO's ROE of -0.04%. Regarding short-term risk, IPCALAB.BO is less volatile compared to PPLPHARMA.BO. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check PPLPHARMA.BO's competition here
Piramal Enterprises Limited (NSE: PEL.NS)
IPCALAB.BO vs PEL.NS Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, PEL.NS has a market cap of 254.9B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while PEL.NS trades at ₹1,124.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas PEL.NS's P/E ratio is 44.24. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to PEL.NS's ROE of +0.01%. Regarding short-term risk, IPCALAB.BO is less volatile compared to PEL.NS. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check PEL.NS's competition here
Shilpa Medicare Limited (NSE: SHILPAMED.NS)
IPCALAB.BO vs SHILPAMED.NS Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, SHILPAMED.NS has a market cap of 210B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while SHILPAMED.NS trades at ₹1,071.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas SHILPAMED.NS's P/E ratio is 68.21. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to SHILPAMED.NS's ROE of +0.12%. Regarding short-term risk, IPCALAB.BO is less volatile compared to SHILPAMED.NS. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check SHILPAMED.NS's competition here
Granules India Limited (BSE: GRANULES.BO)
IPCALAB.BO vs GRANULES.BO Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, GRANULES.BO has a market cap of 208.2B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while GRANULES.BO trades at ₹845.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas GRANULES.BO's P/E ratio is 31.98. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to GRANULES.BO's ROE of +0.15%. Regarding short-term risk, IPCALAB.BO is less volatile compared to GRANULES.BO. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check GRANULES.BO's competition here
Granules India Limited (NSE: GRANULES.NS)
IPCALAB.BO vs GRANULES.NS Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, GRANULES.NS has a market cap of 207.3B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while GRANULES.NS trades at ₹845.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas GRANULES.NS's P/E ratio is 31.78. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to GRANULES.NS's ROE of +0.15%. Regarding short-term risk, IPCALAB.BO is less volatile compared to GRANULES.NS. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check GRANULES.NS's competition here
Caplin Point Laboratories Ltd. (BSE: CAPLIPOINT.BO)
IPCALAB.BO vs CAPLIPOINT.BO Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, CAPLIPOINT.BO has a market cap of 203.8B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while CAPLIPOINT.BO trades at ₹2,650.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas CAPLIPOINT.BO's P/E ratio is 31.48. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to CAPLIPOINT.BO's ROE of +0.21%. Regarding short-term risk, IPCALAB.BO is less volatile compared to CAPLIPOINT.BO. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check CAPLIPOINT.BO's competition here
Caplin Point Laboratories Limited (NSE: CAPLIPOINT.NS)
IPCALAB.BO vs CAPLIPOINT.NS Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, CAPLIPOINT.NS has a market cap of 203.7B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while CAPLIPOINT.NS trades at ₹2,649.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas CAPLIPOINT.NS's P/E ratio is 31.49. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to CAPLIPOINT.NS's ROE of +0.21%. Regarding short-term risk, IPCALAB.BO is less volatile compared to CAPLIPOINT.NS. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check CAPLIPOINT.NS's competition here
Cohance Lifesciences Limited (NSE: COHANCE.NS)
IPCALAB.BO vs COHANCE.NS Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, COHANCE.NS has a market cap of 174.8B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while COHANCE.NS trades at ₹455.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas COHANCE.NS's P/E ratio is 138.20. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to COHANCE.NS's ROE of +0.03%. Regarding short-term risk, IPCALAB.BO is less volatile compared to COHANCE.NS. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check COHANCE.NS's competition here
Cohance Lifesciences Limited (BSE: COHANCE.BO)
IPCALAB.BO vs COHANCE.BO Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, COHANCE.BO has a market cap of 174.5B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while COHANCE.BO trades at ₹455.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas COHANCE.BO's P/E ratio is 144.41. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to COHANCE.BO's ROE of +0.03%. Regarding short-term risk, IPCALAB.BO is less volatile compared to COHANCE.BO. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check COHANCE.BO's competition here
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS)
IPCALAB.BO vs ALIVUS.NS Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, ALIVUS.NS has a market cap of 169.9B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while ALIVUS.NS trades at ₹1,370.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas ALIVUS.NS's P/E ratio is 27.43. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to ALIVUS.NS's ROE of +0.19%. Regarding short-term risk, IPCALAB.BO is less volatile compared to ALIVUS.NS. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check ALIVUS.NS's competition here
Alivus Life Sciences Limited (BSE: ALIVUS.BO)
IPCALAB.BO vs ALIVUS.BO Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, ALIVUS.BO has a market cap of 169.8B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while ALIVUS.BO trades at ₹1,370.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas ALIVUS.BO's P/E ratio is 28.15. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to ALIVUS.BO's ROE of +0.10%. Regarding short-term risk, IPCALAB.BO is less volatile compared to ALIVUS.BO. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check ALIVUS.BO's competition here
Eris Lifesciences Limited (BSE: ERIS.BO)
IPCALAB.BO vs ERIS.BO Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, ERIS.BO has a market cap of 164.6B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while ERIS.BO trades at ₹1,146.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas ERIS.BO's P/E ratio is 38.51. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to ERIS.BO's ROE of +0.19%. Regarding short-term risk, IPCALAB.BO is less volatile compared to ERIS.BO. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check ERIS.BO's competition here
Eris Lifesciences Limited (NSE: ERIS.NS)
IPCALAB.BO vs ERIS.NS Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, ERIS.NS has a market cap of 164.2B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while ERIS.NS trades at ₹1,145.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas ERIS.NS's P/E ratio is 33.51. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to ERIS.NS's ROE of +0.19%. Regarding short-term risk, IPCALAB.BO is less volatile compared to ERIS.NS. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check ERIS.NS's competition here
Alembic Pharmaceuticals Limited (NSE: APLLTD.NS)
IPCALAB.BO vs APLLTD.NS Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, APLLTD.NS has a market cap of 164B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while APLLTD.NS trades at ₹833.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas APLLTD.NS's P/E ratio is 21.84. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to APLLTD.NS's ROE of +0.13%. Regarding short-term risk, IPCALAB.BO is less volatile compared to APLLTD.NS. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check APLLTD.NS's competition here
Alembic Pharmaceuticals Limited (BSE: APLLTD.BO)
IPCALAB.BO vs APLLTD.BO Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, APLLTD.BO has a market cap of 163.9B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while APLLTD.BO trades at ₹833.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas APLLTD.BO's P/E ratio is 21.83. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to APLLTD.BO's ROE of +0.13%. Regarding short-term risk, IPCALAB.BO is less volatile compared to APLLTD.BO. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check APLLTD.BO's competition here
Jubilant Pharmova Limited (BSE: JUBLPHARMA.BO)
IPCALAB.BO vs JUBLPHARMA.BO Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, JUBLPHARMA.BO has a market cap of 156.7B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while JUBLPHARMA.BO trades at ₹974.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas JUBLPHARMA.BO's P/E ratio is 41.00. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to JUBLPHARMA.BO's ROE of +0.05%. Regarding short-term risk, IPCALAB.BO is less volatile compared to JUBLPHARMA.BO. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check JUBLPHARMA.BO's competition here
Jubilant Pharmova Limited (NSE: JUBLPHARMA.NS)
IPCALAB.BO vs JUBLPHARMA.NS Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, JUBLPHARMA.NS has a market cap of 156.7B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while JUBLPHARMA.NS trades at ₹974.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas JUBLPHARMA.NS's P/E ratio is 40.99. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to JUBLPHARMA.NS's ROE of +0.05%. Regarding short-term risk, IPCALAB.BO is less volatile compared to JUBLPHARMA.NS. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check JUBLPHARMA.NS's competition here
AstraZeneca Pharma India Limited (BSE: ASTRAZEN.BO)
IPCALAB.BO vs ASTRAZEN.BO Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, ASTRAZEN.BO has a market cap of 149.7B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while ASTRAZEN.BO trades at ₹5,918.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas ASTRAZEN.BO's P/E ratio is 88.19. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to ASTRAZEN.BO's ROE of +0.20%. Regarding short-term risk, IPCALAB.BO is less volatile compared to ASTRAZEN.BO. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check ASTRAZEN.BO's competition here
AstraZeneca Pharma India Limited (NSE: ASTRAZEN.NS)
IPCALAB.BO vs ASTRAZEN.NS Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, ASTRAZEN.NS has a market cap of 149.5B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while ASTRAZEN.NS trades at ₹5,918.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas ASTRAZEN.NS's P/E ratio is 88.15. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to ASTRAZEN.NS's ROE of +0.20%. Regarding short-term risk, IPCALAB.BO is less volatile compared to ASTRAZEN.NS. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check ASTRAZEN.NS's competition here
Natco Pharma Limited (NSE: NATCOPHARM.NS)
IPCALAB.BO vs NATCOPHARM.NS Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, NATCOPHARM.NS has a market cap of 147.5B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while NATCOPHARM.NS trades at ₹810.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas NATCOPHARM.NS's P/E ratio is 13.58. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to NATCOPHARM.NS's ROE of +0.13%. Regarding short-term risk, IPCALAB.BO is less volatile compared to NATCOPHARM.NS. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check NATCOPHARM.NS's competition here
NATCO Pharma Limited (BSE: NATCOPHARM.BO)
IPCALAB.BO vs NATCOPHARM.BO Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, NATCOPHARM.BO has a market cap of 147.5B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while NATCOPHARM.BO trades at ₹810.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas NATCOPHARM.BO's P/E ratio is 13.59. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to NATCOPHARM.BO's ROE of +0.13%. Regarding short-term risk, IPCALAB.BO is less volatile compared to NATCOPHARM.BO. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check NATCOPHARM.BO's competition here
Glenmark Life Sciences Limited (NSE: GLS.NS)
IPCALAB.BO vs GLS.NS Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, GLS.NS has a market cap of 133.1B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while GLS.NS trades at ₹1,086.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas GLS.NS's P/E ratio is 31.50. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to GLS.NS's ROE of +0.21%. Regarding short-term risk, IPCALAB.BO is less volatile compared to GLS.NS. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check GLS.NS's competition here
Glenmark Life Sciences Limited (BSE: GLS.BO)
IPCALAB.BO vs GLS.BO Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, GLS.BO has a market cap of 133B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while GLS.BO trades at ₹1,085.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas GLS.BO's P/E ratio is 30.23. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to GLS.BO's ROE of +0.09%. Regarding short-term risk, IPCALAB.BO is less volatile compared to GLS.BO. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check GLS.BO's competition here
Sudeep Pharma Ltd. (NSE: SUDEEPPHRM.NS)
IPCALAB.BO vs SUDEEPPHRM.NS Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, SUDEEPPHRM.NS has a market cap of 130.8B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while SUDEEPPHRM.NS trades at ₹1,170.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas SUDEEPPHRM.NS's P/E ratio is 71.64. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to SUDEEPPHRM.NS's ROE of N/A. Regarding short-term risk, IPCALAB.BO is less volatile compared to SUDEEPPHRM.NS. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check SUDEEPPHRM.NS's competition here
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS)
IPCALAB.BO vs AKUMS.NS Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, AKUMS.NS has a market cap of 124.7B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while AKUMS.NS trades at ₹822.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas AKUMS.NS's P/E ratio is 43.13. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to AKUMS.NS's ROE of +0.09%. Regarding short-term risk, IPCALAB.BO is less volatile compared to AKUMS.NS. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check AKUMS.NS's competition here
Caplin Point Laboratories Limited (BSE: CAPPL.BO)
IPCALAB.BO vs CAPPL.BO Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, CAPPL.BO has a market cap of 109.4B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while CAPPL.BO trades at ₹1,446.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas CAPPL.BO's P/E ratio is 50.30. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to CAPPL.BO's ROE of +0.05%. Regarding short-term risk, IPCALAB.BO is less volatile compared to CAPPL.BO. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check CAPPL.BO's competition here
Shilpa Medicare Limited (BSE: SHILPAMED.BO)
IPCALAB.BO vs SHILPAMED.BO Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, SHILPAMED.BO has a market cap of 104.9B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while SHILPAMED.BO trades at ₹1,072.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas SHILPAMED.BO's P/E ratio is 70.37. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to SHILPAMED.BO's ROE of +0.12%. Regarding short-term risk, IPCALAB.BO is less volatile compared to SHILPAMED.BO. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check SHILPAMED.BO's competition here
Viyash Scientific Limited (NSE: VIYASH.NS)
IPCALAB.BO vs VIYASH.NS Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, VIYASH.NS has a market cap of 101.8B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while VIYASH.NS trades at ₹240.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas VIYASH.NS's P/E ratio is 56.06. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to VIYASH.NS's ROE of +0.09%. Regarding short-term risk, IPCALAB.BO is less volatile compared to VIYASH.NS. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check VIYASH.NS's competition here
Strides Pharma Science Limited (NSE: STAR.NS)
IPCALAB.BO vs STAR.NS Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, STAR.NS has a market cap of 100.3B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while STAR.NS trades at ₹1,100.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas STAR.NS's P/E ratio is 16.37. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to STAR.NS's ROE of +0.22%. Regarding short-term risk, IPCALAB.BO is less volatile compared to STAR.NS. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check STAR.NS's competition here
Strides Pharma Science Limited (BSE: STAR.BO)
IPCALAB.BO vs STAR.BO Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, STAR.BO has a market cap of 99.9B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while STAR.BO trades at ₹1,100.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas STAR.BO's P/E ratio is 16.36. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to STAR.BO's ROE of +0.22%. Regarding short-term risk, IPCALAB.BO is less volatile compared to STAR.BO. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check STAR.BO's competition here
Aarti Pharmalabs Limited (NSE: AARTIPHARM.NS)
IPCALAB.BO vs AARTIPHARM.NS Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, AARTIPHARM.NS has a market cap of 88.4B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while AARTIPHARM.NS trades at ₹953.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas AARTIPHARM.NS's P/E ratio is 41.47. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to AARTIPHARM.NS's ROE of +0.10%. Regarding short-term risk, IPCALAB.BO is less volatile compared to AARTIPHARM.NS. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check AARTIPHARM.NS's competition here
Procter & Gamble Health Limited (NSE: PGHL.NS)
IPCALAB.BO vs PGHL.NS Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, PGHL.NS has a market cap of 88.1B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while PGHL.NS trades at ₹5,234.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas PGHL.NS's P/E ratio is 24.69. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to PGHL.NS's ROE of +0.62%. Regarding short-term risk, IPCALAB.BO is less volatile compared to PGHL.NS. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check PGHL.NS's competition here
Procter & Gamble Health Limited (BSE: PGHL.BO)
IPCALAB.BO vs PGHL.BO Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, PGHL.BO has a market cap of 88B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while PGHL.BO trades at ₹5,232.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas PGHL.BO's P/E ratio is 24.61. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to PGHL.BO's ROE of +0.62%. Regarding short-term risk, IPCALAB.BO is less volatile compared to PGHL.BO. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check PGHL.BO's competition here
Aarti Pharmalabs Limited (BSE: AARTIPHARM.BO)
IPCALAB.BO vs AARTIPHARM.BO Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, AARTIPHARM.BO has a market cap of 87.9B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while AARTIPHARM.BO trades at ₹953.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas AARTIPHARM.BO's P/E ratio is 41.46. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to AARTIPHARM.BO's ROE of +0.10%. Regarding short-term risk, IPCALAB.BO is less volatile compared to AARTIPHARM.BO. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check AARTIPHARM.BO's competition here
Morepen Laboratories Limited (NSE: MOREPENLAB.NS)
IPCALAB.BO vs MOREPENLAB.NS Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, MOREPENLAB.NS has a market cap of 78.9B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while MOREPENLAB.NS trades at ₹146.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas MOREPENLAB.NS's P/E ratio is 56.13. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to MOREPENLAB.NS's ROE of +0.12%. Regarding short-term risk, IPCALAB.BO is less volatile compared to MOREPENLAB.NS. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check MOREPENLAB.NS's competition here
Morepen Laboratories Limited (BSE: MOREPENLAB.BO)
IPCALAB.BO vs MOREPENLAB.BO Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, MOREPENLAB.BO has a market cap of 78.8B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while MOREPENLAB.BO trades at ₹146.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas MOREPENLAB.BO's P/E ratio is 83.09. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to MOREPENLAB.BO's ROE of +0.12%. Regarding short-term risk, IPCALAB.BO is less volatile compared to MOREPENLAB.BO. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check MOREPENLAB.BO's competition here
Bliss GVS Pharma Limited (NSE: BLISSGVS.NS)
IPCALAB.BO vs BLISSGVS.NS Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, BLISSGVS.NS has a market cap of 71.7B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while BLISSGVS.NS trades at ₹681.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas BLISSGVS.NS's P/E ratio is 52.54. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to BLISSGVS.NS's ROE of +0.12%. Regarding short-term risk, IPCALAB.BO is less volatile compared to BLISSGVS.NS. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check BLISSGVS.NS's competition here
Bliss GVS Pharma Limited (BSE: BLISSGVS.BO)
IPCALAB.BO vs BLISSGVS.BO Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, BLISSGVS.BO has a market cap of 71.4B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while BLISSGVS.BO trades at ₹677.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas BLISSGVS.BO's P/E ratio is 52.05. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to BLISSGVS.BO's ROE of +0.12%. Regarding short-term risk, IPCALAB.BO is less volatile compared to BLISSGVS.BO. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check BLISSGVS.BO's competition here
Suven Life Sciences Limited (NSE: SUVEN.NS)
IPCALAB.BO vs SUVEN.NS Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, SUVEN.NS has a market cap of 70.5B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while SUVEN.NS trades at ₹305.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas SUVEN.NS's P/E ratio is -21.76. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to SUVEN.NS's ROE of -1.12%. Regarding short-term risk, IPCALAB.BO is less volatile compared to SUVEN.NS. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check SUVEN.NS's competition here
Suven Life Sciences Limited (BSE: SUVEN.BO)
IPCALAB.BO vs SUVEN.BO Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, SUVEN.BO has a market cap of 69.7B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while SUVEN.BO trades at ₹305.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas SUVEN.BO's P/E ratio is -24.93. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to SUVEN.BO's ROE of -1.12%. Regarding short-term risk, IPCALAB.BO is less volatile compared to SUVEN.BO. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check SUVEN.BO's competition here
Innova Captab Limited (NSE: INNOVACAP.NS)
IPCALAB.BO vs INNOVACAP.NS Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, INNOVACAP.NS has a market cap of 65.3B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while INNOVACAP.NS trades at ₹1,166.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas INNOVACAP.NS's P/E ratio is 53.68. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to INNOVACAP.NS's ROE of +0.15%. Regarding short-term risk, IPCALAB.BO is less volatile compared to INNOVACAP.NS. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check INNOVACAP.NS's competition here
Sun Pharma Advanced Research Company Limited (NSE: SPARC.NS)
IPCALAB.BO vs SPARC.NS Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, SPARC.NS has a market cap of 63.9B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while SPARC.NS trades at ₹196.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas SPARC.NS's P/E ratio is 4.11. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to SPARC.NS's ROE of +3.19%. Regarding short-term risk, IPCALAB.BO is less volatile compared to SPARC.NS. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check SPARC.NS's competition here
Sun Pharma Advanced Research Company Limited (BSE: SPARC.BO)
IPCALAB.BO vs SPARC.BO Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, SPARC.BO has a market cap of 63.7B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while SPARC.BO trades at ₹197.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas SPARC.BO's P/E ratio is 4.11. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to SPARC.BO's ROE of +3.19%. Regarding short-term risk, IPCALAB.BO is less volatile compared to SPARC.BO. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check SPARC.BO's competition here
IOL Chemicals and Pharmaceuticals Limited (NSE: IOLCP.NS)
IPCALAB.BO vs IOLCP.NS Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, IOLCP.NS has a market cap of 63.1B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while IOLCP.NS trades at ₹220.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas IOLCP.NS's P/E ratio is 35.11. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to IOLCP.NS's ROE of +0.09%. Regarding short-term risk, IPCALAB.BO is less volatile compared to IOLCP.NS. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check IOLCP.NS's competition here
IOL Chemicals and Pharmaceuticals Limited (BSE: IOLCP.BO)
IPCALAB.BO vs IOLCP.BO Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, IOLCP.BO has a market cap of 63B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while IOLCP.BO trades at ₹220.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas IOLCP.BO's P/E ratio is 35.16. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to IOLCP.BO's ROE of +0.09%. Regarding short-term risk, IPCALAB.BO is less volatile compared to IOLCP.BO. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check IOLCP.BO's competition here
FDC Limited (BSE: FDC.BO)
IPCALAB.BO vs FDC.BO Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, FDC.BO has a market cap of 54.4B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while FDC.BO trades at ₹328.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas FDC.BO's P/E ratio is 19.33. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to FDC.BO's ROE of +0.12%. Regarding short-term risk, IPCALAB.BO is less volatile compared to FDC.BO. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check FDC.BO's competition here
FDC Limited (NSE: FDC.NS)
IPCALAB.BO vs FDC.NS Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, FDC.NS has a market cap of 54.3B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while FDC.NS trades at ₹328.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas FDC.NS's P/E ratio is 19.30. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to FDC.NS's ROE of +0.12%. Regarding short-term risk, IPCALAB.BO is less volatile compared to FDC.NS. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check FDC.NS's competition here
Orchid Pharma Limited (NSE: ORCHPHARMA.NS)
IPCALAB.BO vs ORCHPHARMA.NS Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, ORCHPHARMA.NS has a market cap of 51.1B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while ORCHPHARMA.NS trades at ₹1,023.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas ORCHPHARMA.NS's P/E ratio is 162.35. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to ORCHPHARMA.NS's ROE of +0.01%. Regarding short-term risk, IPCALAB.BO is less volatile compared to ORCHPHARMA.NS. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check ORCHPHARMA.NS's competition here
Orchid Pharma Limited (BSE: ORCHPHARMA.BO)
IPCALAB.BO vs ORCHPHARMA.BO Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, ORCHPHARMA.BO has a market cap of 51B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while ORCHPHARMA.BO trades at ₹1,025.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas ORCHPHARMA.BO's P/E ratio is 78.40. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to ORCHPHARMA.BO's ROE of +0.01%. Regarding short-term risk, IPCALAB.BO is less volatile compared to ORCHPHARMA.BO. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check ORCHPHARMA.BO's competition here
Novartis India Limited (BSE: NOVARTIND.BO)
IPCALAB.BO vs NOVARTIND.BO Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, NOVARTIND.BO has a market cap of 50.6B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while NOVARTIND.BO trades at ₹2,011.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas NOVARTIND.BO's P/E ratio is 53.32. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to NOVARTIND.BO's ROE of +0.12%. Regarding short-term risk, IPCALAB.BO is less volatile compared to NOVARTIND.BO. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check NOVARTIND.BO's competition here
Novartis India Limited (NSE: NOVARTIND.NS)
IPCALAB.BO vs NOVARTIND.NS Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, NOVARTIND.NS has a market cap of 50.6B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while NOVARTIND.NS trades at ₹2,010.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas NOVARTIND.NS's P/E ratio is 53.37. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to NOVARTIND.NS's ROE of +0.12%. Regarding short-term risk, IPCALAB.BO is less volatile compared to NOVARTIND.NS. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check NOVARTIND.NS's competition here
Sequent Scientific Limited (BSE: SEQUENT.BO)
IPCALAB.BO vs SEQUENT.BO Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, SEQUENT.BO has a market cap of 50.6B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while SEQUENT.BO trades at ₹202.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas SEQUENT.BO's P/E ratio is 123.41. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to SEQUENT.BO's ROE of +0.08%. Regarding short-term risk, IPCALAB.BO is less volatile compared to SEQUENT.BO. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check SEQUENT.BO's competition here
Sequent Scientific Limited (NSE: SEQUENT.NS)
IPCALAB.BO vs SEQUENT.NS Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, SEQUENT.NS has a market cap of 50.6B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while SEQUENT.NS trades at ₹202.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas SEQUENT.NS's P/E ratio is 124.17. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to SEQUENT.NS's ROE of +0.08%. Regarding short-term risk, IPCALAB.BO is less volatile compared to SEQUENT.NS. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check SEQUENT.NS's competition here
RPG Life Sciences Limited (BSE: RPGLIFE.BO)
IPCALAB.BO vs RPGLIFE.BO Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, RPGLIFE.BO has a market cap of 48.9B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while RPGLIFE.BO trades at ₹2,897.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas RPGLIFE.BO's P/E ratio is 42.18. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to RPGLIFE.BO's ROE of +0.21%. Regarding short-term risk, IPCALAB.BO is less volatile compared to RPGLIFE.BO. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check RPGLIFE.BO's competition here
RPG Life Sciences Limited (NSE: RPGLIFE.NS)
IPCALAB.BO vs RPGLIFE.NS Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, RPGLIFE.NS has a market cap of 48.5B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while RPGLIFE.NS trades at ₹2,892.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas RPGLIFE.NS's P/E ratio is 42.12. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to RPGLIFE.NS's ROE of +0.21%. Regarding short-term risk, IPCALAB.BO is less volatile compared to RPGLIFE.NS. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check RPGLIFE.NS's competition here
Gufic Biosciences Limited (NSE: GUFICBIO.NS)
IPCALAB.BO vs GUFICBIO.NS Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, GUFICBIO.NS has a market cap of 42.9B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while GUFICBIO.NS trades at ₹422.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas GUFICBIO.NS's P/E ratio is 58.40. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to GUFICBIO.NS's ROE of +0.11%. Regarding short-term risk, IPCALAB.BO is less volatile compared to GUFICBIO.NS. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check GUFICBIO.NS's competition here
Gufic Biosciences Limited (BSE: GUFICBIO.BO)
IPCALAB.BO vs GUFICBIO.BO Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, GUFICBIO.BO has a market cap of 42.9B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while GUFICBIO.BO trades at ₹422.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas GUFICBIO.BO's P/E ratio is 58.38. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to GUFICBIO.BO's ROE of +0.11%. Regarding short-term risk, IPCALAB.BO is less volatile compared to GUFICBIO.BO. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check GUFICBIO.BO's competition here
Gujarat Themis Biosyn Limited (BSE: GUJTHEM.BO)
IPCALAB.BO vs GUJTHEM.BO Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, GUJTHEM.BO has a market cap of 42.6B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while GUJTHEM.BO trades at ₹379.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas GUJTHEM.BO's P/E ratio is 87.37. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to GUJTHEM.BO's ROE of +0.18%. Regarding short-term risk, IPCALAB.BO is less volatile compared to GUJTHEM.BO. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check GUJTHEM.BO's competition here
Gujarat Themis Biosyn Ltd. (NSE: GUJTHEM.NS)
IPCALAB.BO vs GUJTHEM.NS Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, GUJTHEM.NS has a market cap of 42.5B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while GUJTHEM.NS trades at ₹379.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas GUJTHEM.NS's P/E ratio is 90.70. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to GUJTHEM.NS's ROE of +0.18%. Regarding short-term risk, IPCALAB.BO is less volatile compared to GUJTHEM.NS. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check GUJTHEM.NS's competition here
Aarti Drugs Limited (NSE: AARTIDRUGS.NS)
IPCALAB.BO vs AARTIDRUGS.NS Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, AARTIDRUGS.NS has a market cap of 39.1B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while AARTIDRUGS.NS trades at ₹417.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas AARTIDRUGS.NS's P/E ratio is 20.18. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to AARTIDRUGS.NS's ROE of +0.13%. Regarding short-term risk, IPCALAB.BO is less volatile compared to AARTIDRUGS.NS. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check AARTIDRUGS.NS's competition here
Aarti Drugs Limited (BSE: AARTIDRUGS.BO)
IPCALAB.BO vs AARTIDRUGS.BO Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, AARTIDRUGS.BO has a market cap of 39.1B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while AARTIDRUGS.BO trades at ₹416.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas AARTIDRUGS.BO's P/E ratio is 20.16. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to AARTIDRUGS.BO's ROE of +0.13%. Regarding short-term risk, IPCALAB.BO is less volatile compared to AARTIDRUGS.BO. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check AARTIDRUGS.BO's competition here
Unichem Laboratories Limited (NSE: UNICHEMLAB.NS)
IPCALAB.BO vs UNICHEMLAB.NS Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, UNICHEMLAB.NS has a market cap of 38.6B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while UNICHEMLAB.NS trades at ₹546.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas UNICHEMLAB.NS's P/E ratio is 12.66. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to UNICHEMLAB.NS's ROE of +0.12%. Regarding short-term risk, IPCALAB.BO is less volatile compared to UNICHEMLAB.NS. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check UNICHEMLAB.NS's competition here
Unichem Laboratories Limited (BSE: UNICHEMLAB.BO)
IPCALAB.BO vs UNICHEMLAB.BO Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, UNICHEMLAB.BO has a market cap of 38.6B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while UNICHEMLAB.BO trades at ₹545.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas UNICHEMLAB.BO's P/E ratio is 12.64. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to UNICHEMLAB.BO's ROE of +0.12%. Regarding short-term risk, IPCALAB.BO is less volatile compared to UNICHEMLAB.BO. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check UNICHEMLAB.BO's competition here
Ind-Swift Laboratories Limited (NSE: INDSWFTLAB.NS)
IPCALAB.BO vs INDSWFTLAB.NS Comparison October 2026
Ipca Laboratories Limited (BSE: IPCALAB.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IPCALAB.BO stands at 497.4B. In comparison, INDSWFTLAB.NS has a market cap of 34.8B. Regarding current trading prices, IPCALAB.BO is priced at ₹1,939.15 on the BSE, while INDSWFTLAB.NS trades at ₹391.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IPCALAB.BO currently has a P/E ratio of 36.76, whereas INDSWFTLAB.NS's P/E ratio is 58.71. In terms of profitability, IPCALAB.BO's ROE is +0.16%, compared to INDSWFTLAB.NS's ROE of +0.04%. Regarding short-term risk, IPCALAB.BO is less volatile compared to INDSWFTLAB.NS. This indicates lower risk in terms of short-term price fluctuations for IPCALAB.BO.Check INDSWFTLAB.NS's competition here